GLOPID-R

GloPID-R member

Japan Agency for Medical Research and Development (AMED)

About AMED

The Japan Agency for Medical Research and Development (AMED) was established in 2015 as a national funding agency for medical research and development. Its mission is to promote medical research and development leading to practical applications.

AMED recognizes the importance of global cooperation and has developed partnerships with other research funding agencies and international initiatives to further strengthen our worldwide network.

In his own words

Shoji Miyagawa, DVM, MS., GloPID-R co-chair

“AMED promotes integrated research and development in medicine, from basic research to clinical trials. As a GloPID-R member, we strive to facilitate rapid and effective medical R&D as well as to facilitate collaboration with global and regional partners focusing on preparedness for emerging and re-emerging infectious disease outbreaks with pandemic potential.”
Shoji Miyagawa, DVM, MS., GloPID-R co-chair

Our Work

AMED supports collaborative research projects at our 10 overseas research centers, located in infectious disease endemic areas. These centers are operated by Japanese universities in 7 Asian countries (China, Indonesia, Myanmar, the Philippines, Thailand, Vietnam, India) and 3 African countries (Ghana, Zambia, DRC). Epidemiology, cohort studies and genome sequencing are conducted via these research centers, strengthening human resources and building strong collaboration with local research institutions and government agencies. The work carried out by this program is contributing to the development of new diagnostics, therapeutics and vaccines.

AMED promotes international collaborative research projects on infectious diseases:

  • Strategic International Collaborative Research Program (SICORP): A joint call implemented in 2019 with UK-MRC and based on inter-ministerial agreements with other countries. 8 joint research projects are being conducted between 2020 and 2022.
  • e-ASIA Joint Research Program: A joint call is implemented annually. The aim is to solve issues commonly shared across Asia on cancer and infectious diseases through multilateral collaboration.
  • U.S.-Japan Cooperative Medical Sciences Program: Launched more than 50 years ago under a bilateral agreement between the United States and Japan, this program promotes U.S.-Japan collaboration on 10 different disease areas including viral diseases, HIV/AIDS, Hepatitis and Parasitic diseases.
  • Science and Technology Research Partnership for Sustainable Development (SATREPS) is an international project for collaborative research that, alongside official development assistance (ODA), aims to resolve global-scale issues with developing countries. AMED leads the research carried out in the field of infectious disease control.
  • International Collaborative Research Program for Tackling the NTDs (Neglected Tropical Diseases) Challenges in African countries aims to contribute to the control of NTDs. It covers medical and public hygiene research and development, ranging from basic research to the establishment of methods for diagnosis, surveillance, prevention, drug discovery and treatment.

Various research projects and activities are ongoing to prepare for, or respond to, future epidemics and pandemics.

In one of these projects, we have established networks among research institutes in Asian countries to promote collaborative research for epidemiological and pathogenic analysis for disease agents and to develop diagnostic tests. This means that accurate and reliable data can be shared among the network countries.

In another project, Japan is working with other Asian countries to develop human resources for clinical trials, to establish systems based on the needs of major hospitals, and build clinical trial networks. In addition, we promote regulatory harmonization, international joint clinical research and clinical trials in Japan and Asian countries.

AMED fosters international collaboration on medical research and development and has forged partnerships with NIH / NAM in the U.S., MRC in U.K., NHMRC in Australia, CIHR in Canada, SEIDI/AEI in Spain, A*STAR in Singapore, NordForsk in Finland, Norway and Sweden, and the Ministry of Health in Lithuania. In addition, AMED participates in various international alliances and consortia to strengthen multilateral collaboration.

Did you know?

AMED is involved in collaborative projects with organizations in approximately 30 different countries, and more than half of these focus on infectious diseases.

EU Flag

The GloPID-R Secretariat is a project which receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874667.